Using a virus to deliver the genetic tool worked better than other methods, with about 80% of liver cancer cells taking up the treatment successfully.

Scientific Claim

Lentivirus-mediated siRNA delivery was effective for silencing ER-α in Hep3B and HCCLM3 human hepatocellular carcinoma cell lines, with higher infection efficiency than liposome-based methods.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The study directly measured infection efficiency in cell cultures and compared it to previous liposome methods. The claim accurately reports the observed efficiency without overgeneralizing.

Source Excerpt

“Our results showed that the rate of lentivirus-mediated siRNA infection reached 80% which is much higher than that of liposome transfection we once used in our pretest.”

Evidence from Studies

Supporting Evidence (1)

Why it supports

The study directly compared infection efficiency between lentiviral and liposomal methods, reporting 80% efficiency for lentivirus versus lower efficiency for liposomes in pretest experiments.

Score

Unknown Title

Cross-Sectional Study

Supported

Source Study

Unknown Title

DOI: 10.1155/2015/490681

Similar Assertions

Using a virus to deliver the genetic tool worked better than other methods, with about 80% of liver cancer cells taking up the treatment successfully.

93%

Using a special virus to deliver a genetic tool that blocks ER-α gene activity successfully lowered ER-α levels in liver cancer cells within a day or two.

90%

When using a control that doesn't block ER-α, there was no change in cancer cell growth, invasion, or death compared to normal cells.

82%

When using a control that doesn't block ER-α, there was no change in cancer cell growth, invasion, or death compared to normal cells.

76%